Roche: Rituxan wins FDA approval for rare skin condition
(CercleFinance.com) - Genentech, a unit of Swiss pharma giant Roche, said on Friday that it got approval from the US Food and Drug Administration for its auto-immune disease drug Rituxan to treat pemphigus vulgaris, a rare condition characterized by progressive painful blistering of the skin.
Rituxan is the first biologic therapy approved by the FDA for pemphigus vulgaris and the first major advancement in the treatment of the disease in over 60 years, Genentech said.
The FDA previously granted priority review, breakthrough therapy designation and orphan drug designation to Rituxan for the treatment of pemphigus vulgaris.
With today's decision from FDA, Rituxan is now approved to treat four auto-immune diseases, Roche's biotech division said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Rituxan is the first biologic therapy approved by the FDA for pemphigus vulgaris and the first major advancement in the treatment of the disease in over 60 years, Genentech said.
The FDA previously granted priority review, breakthrough therapy designation and orphan drug designation to Rituxan for the treatment of pemphigus vulgaris.
With today's decision from FDA, Rituxan is now approved to treat four auto-immune diseases, Roche's biotech division said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.